280 related articles for article (PubMed ID: 32827752)
1. Comparison of efficacy and safety of empagliflozin vs linagliptin added to premixed insulin in patients with uncontrolled type 2 diabetes: A randomized, open-label study.
Liu SC; Lee CC; Chuang SM; Sun FJ; Zeng YH
Diabetes Metab; 2021 May; 47(3):101184. PubMed ID: 32827752
[TBL] [Abstract][Full Text] [Related]
2. Effect of empagliflozin versus linagliptin on body composition in Asian patients with type 2 diabetes treated with premixed insulin.
Zeng YH; Liu SC; Lee CC; Sun FJ; Liu JJ
Sci Rep; 2022 Oct; 12(1):17065. PubMed ID: 36224294
[TBL] [Abstract][Full Text] [Related]
3. Empagliflozin/Linagliptin: Combination therapy in patients with type 2 diabetes.
Tan X; Hu J
Ann Endocrinol (Paris); 2016 Oct; 77(5):557-562. PubMed ID: 27062036
[TBL] [Abstract][Full Text] [Related]
4. Empagliflozin/Linagliptin: A Review in Type 2 Diabetes.
Kim ES; Deeks ED
Drugs; 2015 Sep; 75(13):1547-57. PubMed ID: 26323340
[TBL] [Abstract][Full Text] [Related]
5. Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.
Triplitt C; Solis-Herrera C; Cersosimo E; Abdul-Ghani M; Defronzo RA
Expert Opin Pharmacother; 2015; 16(18):2819-33. PubMed ID: 26583910
[TBL] [Abstract][Full Text] [Related]
6. Empagliflozin/linagliptin single-tablet combination: first-in-class treatment option.
Woo V
Int J Clin Pract; 2015 Dec; 69(12):1427-37. PubMed ID: 26303997
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia.
Rosenstock J; Seman LJ; Jelaska A; Hantel S; Pinnetti S; Hach T; Woerle HJ
Diabetes Obes Metab; 2013 Dec; 15(12):1154-60. PubMed ID: 23906374
[TBL] [Abstract][Full Text] [Related]
8. Combination of empagliflozin and linagliptin improves blood pressure and vascular function in type 2 diabetes.
Jung S; Bosch A; Kannenkeril D; Karg MV; Striepe K; Bramlage P; Ott C; Schmieder RE
Eur Heart J Cardiovasc Pharmacother; 2020 Nov; 6(6):364-371. PubMed ID: 31816038
[TBL] [Abstract][Full Text] [Related]
9. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin.
DeFronzo RA; Lewin A; Patel S; Liu D; Kaste R; Woerle HJ; Broedl UC
Diabetes Care; 2015 Mar; 38(3):384-93. PubMed ID: 25583754
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes.
Rizos CV; Filippatos TD; Elisaf MS
Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):117-125. PubMed ID: 29241374
[TBL] [Abstract][Full Text] [Related]
11. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Lingvay I
Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
[TBL] [Abstract][Full Text] [Related]
12. Safety and Tolerability of Combinations of Empagliflozin and Linagliptin in Patients with Type 2 Diabetes: Pooled Data from Two Randomized Controlled Trials.
DeFronzo RA; Lee C; Kohler S
Adv Ther; 2018 Jul; 35(7):1009-1022. PubMed ID: 29949041
[TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability of empagliflozin and linagliptin combination therapy in patients with type 2 diabetes mellitus: a pooled analysis of data from five randomized, controlled clinical trials.
Watada H; Yamauchi T; Yamamoto F; Taniguchi A; Yarush L; Heilmann C; Yasui A
Expert Opin Drug Saf; 2020 Sep; 19(9):1193-1202. PubMed ID: 32552153
[TBL] [Abstract][Full Text] [Related]
14. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial.
Rosenstock J; Jelaska A; Zeller C; Kim G; Broedl UC; Woerle HJ;
Diabetes Obes Metab; 2015 Oct; 17(10):936-48. PubMed ID: 26040302
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the efficacy and safety of empagliflozin addition to insulin and oral antidiabetic medication (OAD) regimen in poorly controlled type 2 diabetes and obese patients.
Sharif H; Sheikh SS; Salman A; Jawed Z; Karim I; Sohail T; Mohsin N
Pak J Pharm Sci; 2024 Mar; 37(2):357-366. PubMed ID: 38767103
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial.
Laffel LM; Danne T; Klingensmith GJ; Tamborlane WV; Willi S; Zeitler P; Neubacher D; Marquard J;
Lancet Diabetes Endocrinol; 2023 Mar; 11(3):169-181. PubMed ID: 36738751
[TBL] [Abstract][Full Text] [Related]
17. Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial.
Kawamori R; Haneda M; Suzaki K; Cheng G; Shiki K; Miyamoto Y; Solimando F; Lee C; Lee J; George J
Diabetes Obes Metab; 2018 Sep; 20(9):2200-2209. PubMed ID: 29766636
[TBL] [Abstract][Full Text] [Related]
18. Linagliptin as add-on to empagliflozin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two-part, randomized, placebo-controlled trial.
Kaku K; Haneda M; Tanaka Y; Lee G; Shiki K; Miyamoto Y; Solimando F; Lee J; Lee C; George J
Diabetes Obes Metab; 2019 Jan; 21(1):136-145. PubMed ID: 30091172
[TBL] [Abstract][Full Text] [Related]
19. Rationality, Efficacy, Tolerability of Empagliflozin Plus Linagliptin Combination for the Management of Type 2 Diabetes Mellitus: A Systematic Review of Randomized Controlled Trials and Observational Studies.
Chenchula S; Varthya SB; Padmavathi R
Curr Diabetes Rev; 2022; 18(4):e100921196392. PubMed ID: 34514991
[TBL] [Abstract][Full Text] [Related]
20. A safety evaluation of empagliflozin plus linagliptin for treating type 2 diabetes.
Gallwitz B
Expert Opin Drug Saf; 2017 Dec; 16(12):1399-1405. PubMed ID: 28934557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
